×
About 1,855 results

ALLMedicine™ Ependymoma Center

Research & Reviews  691 results

MRI-based texture analysis for differentiate between pediatric posterior fossa ependymo...
https://doi.org/10.1016/j.ejrad.2022.110288
European Journal of Radiology; Cui Z, Ren G et. al.

May 15th, 2022 - The aim of the study was to evaluate the feasibility of texture analysis in differentiating between posterior fossa ependymoma type A (PF-EPN-A) and type B (PF-EPN-B) among children. Our retrospective study included 43 patients (37 PF-EPN-A and 6 ...

Resection of Giant Remote Recurrence of Ependymoma After 41 Years.
https://doi.org/10.1016/j.wneu.2022.04.011
World Neurosurgery; Peto I, Krafft PR et. al.

Apr 13th, 2022 - Ependymomas are rare primary tumors of the brain and spinal cord that arises from the ependymal cell layer. Cranial ependymomas commonly occur in the posterior fossa; however, approximately 30% of all tumors can be found in the supratentorial regi...

International HIT-MED Registry (I-HIT-MED)
https://clinicaltrials.gov/ct2/show/NCT02417324

Apr 12th, 2022 - The following patients can be included in this registry: Children and adults with Medulloblastoma (MB) Ependymoma CNS-primitive neuroectodermal tumours (CNS-PNET) including CNS neuroblastoma, CNS ganglioneuroblastoma, Medulloepithelioma, Ependymob...

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
https://clinicaltrials.gov/ct2/show/NCT04743661

Apr 8th, 2022 - Stratum 1: This is a phase 2 single-arm open-label study that will define event-free survival (EFS) and overall survival (OS) following therapy with irinotecan, temozolomide, bevacizumab, and compartmental (intraOmmaya) radioimmunotherapy (cRIT) 1...

see more →

Drugs  10 results see all →

Clinicaltrials.gov  20 results

International HIT-MED Registry (I-HIT-MED)
https://clinicaltrials.gov/ct2/show/NCT02417324

Apr 12th, 2022 - The following patients can be included in this registry: Children and adults with Medulloblastoma (MB) Ependymoma CNS-primitive neuroectodermal tumours (CNS-PNET) including CNS neuroblastoma, CNS ganglioneuroblastoma, Medulloepithelioma, Ependymob...

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
https://clinicaltrials.gov/ct2/show/NCT04743661

Apr 8th, 2022 - Stratum 1: This is a phase 2 single-arm open-label study that will define event-free survival (EFS) and overall survival (OS) following therapy with irinotecan, temozolomide, bevacizumab, and compartmental (intraOmmaya) radioimmunotherapy (cRIT) 1...

Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
https://clinicaltrials.gov/ct2/show/NCT04049669

Mar 25th, 2022 - Disease-specific Cohorts : Cohort 1A, 1B: progressive glioblastoma (relapsed or refractory) Cohort 2A, 2B: progressive medulloblastoma (relapsed or refractory) Cohort 3A, 3B, 3C: progressive ependymoma (relapsed or refractory) Cohort 4C: newly-dia...

A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
https://clinicaltrials.gov/ct2/show/NCT04978727

Mar 3rd, 2022 - This is a multicenter pilot study of SurVaxM (SVN53-67/M57-KLH) for children and young adults with progressive or relapsed medulloblastoma, high grade glioma, ependymoma and newly diagnosed diffuse intrinsic pontine glioma. Survivin (BIRC5) is an ...

Everolimus for Children With Recurrent or Progressive Ependymoma
https://clinicaltrials.gov/ct2/show/NCT02155920

Feb 2nd, 2022 - Ependymoma is the third most common central nervous system neoplasm in children, accounting for approximately 10% of childhood brain tumors. Although the prognosis for children with newly-diagnosed completely resected ependymomas is often good, ch...

see more →

News  18 results

Common Diabetes Drug Shrinks Brain Tumors in Mice
https://www.medscape.com/viewarticle/962161

Nov 3rd, 2021 - Many cancers with known genetic causes can be treated by targeting tumors and leaving healthy cells unscathed. But that's not the case for a rare type of brain and spinal cord cancer that primarily strikes children and has no obvious genetic cause...

Persistent Development of WEE1 Pathway Inhibitors Begins to Pay Off
https://www.onclive.com/view/persistent-development-of-wee1-pathway-inhibitors-begins-to-pay-off

Aug 25th, 2021 - WEE1 is a key regulator of the cell cycle that has been a target of cancer drug discovery efforts for more than a decade. The lead novel candidate, the WEE1 inhibitor adavosertib (AZD1775), has been tested in more than 50 completed or ongoing clin...

FDA Grants Rare Pediatric Disease Designation to WP1066 for Ependymoma
https://www.onclive.com/view/fda-grants-rare-pediatric-disease-designation-to-wp1066-for-ependymoma

Apr 14th, 2021 - The FDA has granted a rare pediatric disease (RPD) designation to the p-STAT3 inhibitor WP1066 for the treatment of patients with ependymoma, a rare type of tumor that can develop in the brain or the spinal cord.1 The FDA’s recognition of the h...

Dr. Upadhyaya on Radiation Therapy for Young Children with Ependymoma
https://www.onclive.com/view/dr-upadhyaya-on-radiation-therapy-for-young-children-with-ependymoma

Dec 20th, 2020 - Santhosh Upadhyaya, MD, neuro-oncologist, St. Jude Children’s Research Hospital, discusses radiation therapy for young children under the age of 3 who have ependymoma. He highlighted outcomes of the 10-year-long SJYC07 trial at the 2018 ASCO Annua...

Medulloblastoma Subtypes Are Different Diseases
https://www.onclive.com/view/medulloblastoma-subtypes-are-different-diseases

Dec 5th, 2020 - Medulloblastoma, a malignant brain tumor that most commonly affects children, is not one disease but several, said researchers with St. Jude Children’s Hospital in Memphis, Tennessee. Similar discoveries have been made in other cancers, leading to...

see more →

Patient Education  3 results see all →